Boosting the accuracy of existing models by updating and extending: using a multicenter COVID-19 ICU cohort as a proxy.

Publication date: Nov 01, 2024

Most published prediction models for Coronavirus Disease 2019 (COVID-19) were poorly reported, at high risk of bias, and heterogeneous in model performance. To tackle methodological challenges faced in previous prediction studies, we investigated whether model updating and extending improves mortality prediction, using the Intensive Care Unit (ICU) as a proxy. All COVID-19 patients admitted to seven ICUs in the Euregio-Meuse Rhine during the first pandemic wave were included. The 4C Mortality and SEIMC scores were selected as promising prognostic models from an external validation study. Five predictors could be estimated based on cohort size. TRIPOD guidelines were followed and logistic regression analyses with the linear predictor, APACHE II score, and country were performed. Bootstrapping with backward selection was applied to select variables for the final model. Additionally, shrinkage was performed. Model discrimination was displayed as optimism-corrected areas under the ROC curve and calibration by calibration slopes and plots. The mortality rate of the 551 included patients was 36%. Discrimination of the 4C Mortality and SEIMC scores increased from 0. 70 to 0. 74 and 0. 70 to 0. 73 and calibration plots improved compared to the original models after updating and extending. Mortality prediction can be improved after updating and extending of promising models.

Open Access PDF

Concepts Keywords
Boosting Aged
Bootstrapping Cohort Studies
Coronavirus COVID-19
Covid Female
Pandemic Humans
Intensive Care Units
Male
Middle Aged
Prognosis
ROC Curve
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
disease IDO country
drug DRUGBANK Saquinavir
drug DRUGBANK Coenzyme M
drug DRUGBANK Zoledronic acid
disease IDO quality
disease MESH Infectious Diseases
disease IDO immunodeficiency
disease MESH Coma
drug DRUGBANK Oxygen
disease MESH Obesity
disease MESH Dyslipidemia
disease MESH Diabetes mellitus
disease MESH Hypertension
disease MESH liver disease
disease MESH lung disease
disease MESH Chronic kidney disease
disease MESH cardiac disease
disease MESH Dementia
disease MESH Connective tissue disease
disease MESH aids
disease MESH Malignancy
disease MESH Emergency
drug DRUGBANK Creatinine
disease MESH pneumonia
disease IDO process
disease MESH respiratory failure
disease MESH death
disease MESH privacy
disease MESH infection
disease IDO intervention
disease MESH morbidity
disease MESH critically ill
disease MESH comorbidity
pathway REACTOME Reproduction

Original Article

(Visited 6 times, 1 visits today)